Literature DB >> 21285516

Comparison of different miR-21 inhibitor chemistries in a cardiac disease model.

Thomas Thum, Nelson Chau, Balkrishen Bhat, Shashi Kumar Gupta, Peter S Linsley, Johann Bauersachs, Stefan Engelhardt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21285516      PMCID： PMC3026747          DOI： 10.1172/JCI45938

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  3 in total

1.  Stress-dependent cardiac remodeling occurs in the absence of microRNA-21 in mice.

Authors:  David M Patrick; Rusty L Montgomery; Xiaoxia Qi; Susanna Obad; Sakari Kauppinen; Joseph A Hill; Eva van Rooij; Eric N Olson
Journal:  J Clin Invest       Date:  2010-10-18       Impact factor: 14.808

2.  miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis.

Authors:  Gang Liu; Arnaud Friggeri; Yanping Yang; Jadranka Milosevic; Qiang Ding; Victor J Thannickal; Naftali Kaminski; Edward Abraham
Journal:  J Exp Med       Date:  2010-07-19       Impact factor: 14.307

3.  MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts.

Authors:  Thomas Thum; Carina Gross; Jan Fiedler; Thomas Fischer; Stephan Kissler; Markus Bussen; Paolo Galuppo; Steffen Just; Wolfgang Rottbauer; Stefan Frantz; Mirco Castoldi; Jürgen Soutschek; Victor Koteliansky; Andreas Rosenwald; M Albert Basson; Jonathan D Licht; John T R Pena; Sara H Rouhanifard; Martina U Muckenthaler; Thomas Tuschl; Gail R Martin; Johann Bauersachs; Stefan Engelhardt
Journal:  Nature       Date:  2008-11-30       Impact factor: 49.962
  3 in total
  40 in total

Review 1.  Antisense MicroRNA Therapeutics in Cardiovascular Disease: Quo Vadis?

Authors:  Leonne E Philippen; Ellen Dirkx; Jan B M Wit; Koos Burggraaf; Leon J de Windt; Paula A da Costa Martins
Journal:  Mol Ther       Date:  2015-07-28       Impact factor: 11.454

2.  miR-145 Contributes to Hypertrophic Scarring of the Skin by Inducing Myofibroblast Activity.

Authors:  Christiane Gras; Dominica Ratuszny; Catarina Hadamitzky; Haijiao Zhang; Rainer Blasczyk; Constança Figueiredo
Journal:  Mol Med       Date:  2015-04-09       Impact factor: 6.354

Review 3.  MicroRNAs as mediators and therapeutic targets in chronic kidney disease.

Authors:  Johan M Lorenzen; Hermann Haller; Thomas Thum
Journal:  Nat Rev Nephrol       Date:  2011-03-22       Impact factor: 28.314

Review 4.  Therapeutic use of microRNAs in myocardial diseases.

Authors:  Michael V G Latronico; Gianlugi Condorelli
Journal:  Curr Heart Fail Rep       Date:  2011-09

Review 5.  Epigenetic mechanisms underlying cardiac degeneration and regeneration.

Authors:  Pankaj Chaturvedi; Suresh C Tyagi
Journal:  Int J Cardiol       Date:  2014-02-20       Impact factor: 4.164

Review 6.  MicroRNAs in hypertension: mechanisms and therapeutic targets.

Authors:  Sándor Bátkai; Thomas Thum
Journal:  Curr Hypertens Rep       Date:  2012-02       Impact factor: 5.369

7.  Circulating and urinary microRNA profile in focal segmental glomerulosclerosis: a pilot study.

Authors:  Ali Ramezani; Joseph M Devaney; Scott Cohen; Maria R Wing; Richard Scott; Susan Knoblach; Rishi Singhal; Lilian Howard; Jeffrey B Kopp; Dominic S Raj
Journal:  Eur J Clin Invest       Date:  2015-04       Impact factor: 4.686

Review 8.  Role of microRNAs in the reperfused myocardium towards post-infarct remodelling.

Authors:  Hongyan Zhu; Guo-Chang Fan
Journal:  Cardiovasc Res       Date:  2011-10-28       Impact factor: 10.787

Review 9.  Molecular switches under TGFβ signalling during progression from cardiac hypertrophy to heart failure.

Authors:  J Heger; R Schulz; G Euler
Journal:  Br J Pharmacol       Date:  2015-11-16       Impact factor: 8.739

Review 10.  Regulation and function of miRNA-21 in health and disease.

Authors:  Regalla Kumarswamy; Ingo Volkmann; Thomas Thum
Journal:  RNA Biol       Date:  2011-07-07       Impact factor: 4.652
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.